R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal Article
Hexamethylene bisacetamide-induced cutaneous vasculitis.
TL;DR: Nonthrombocytopenic purpura developed in a patient receiving hexamethylene bisacetamide, a tumor-differentiating agent in vitro that is in phase I clinical trials, and revealed features of leukocytoclastic vasculitis with deposition of IgA and complement in the dermal vasculature.
Journal ArticleDOI
Exposure-response (E-R) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer.
Min Zhu,Rui Tang,Sameer Doshi,Kelly S. Oliner,Steven Kathman,Per Olsson Gisleskog,Sarita Dubey,Yizhou Jiang,Ross C. Donehower,Timothy Iveson,Elwyn Loh +10 more
TL;DR: R (7.5 or 15 mg/kg) + ECX showed trends for improved overall survival (OS) and progression-free survival (PFS) compared to ECX alone in a double-blind, placebo-controlled, phase 2 trial of 121 pts with G/EGJ cancer.
Journal ArticleDOI
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.
E. Claire Dees,Eric K. Rowinsky,Dennis A. Noe,Seamus O’Reilly,Alex A. Adjei,Kathy Elza-Brown,Ross C. Donehower +6 more
TL;DR: Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin, and recommended doses for further study of this combination are PZA 600 mg/m2 over 3 h and cisPlatin 50 mg/ m2 followed by G-CSF support.
Journal ArticleDOI
Growing Pains: a Simulation-Based Curriculum for Improving the Transition to Hematology/Oncology Fellowship.
TL;DR: It is hypothesize that proactively introducing fellows to these high-yield activities will translate into improved patient care and reduced stress for trainees, and is amongst the first oncology fellowship training programs to systematically implement simulation-based curricula into the curriculum.
Journal ArticleDOI
Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancer.
Brandon R. Shank,Amy Hatfield Seung,Katharine Kinsman,Matthew J Newman,Ross C. Donehower,Bradley Burton +5 more
TL;DR: The small sample size did not allow us to detect differences in efficacy or adverse event rates, and thus a larger study would be required to confirm the findings that efficacy was not compromised nor adverse effects greater.